Appointed
Shawn Roman
Chief Operating Officer
APYX ·
Apyx Medical Corp
following the prior announcement that it had appointed Shawn Roman as its Chief Operating Officer
Ready 8-Ks
24
Latest filing
May 21, 2026, 4:23 PM ET
Top materiality
0.85
Event mix
earnings ×12 · other_material ×5 · regulatory ×3
Sentiment
10 pos · 4 neg · 10 neu
Latest earnings
reported 2024-Q2
Executive change
recent →
Recent 8-K filings for APYX
Highest-materiality recent filing
Apyx Medical Q3 revenue down 4% to $11.5M; cuts FY24 guidance; workforce –25%
- Net loss $4.7M ($0.14/share) vs $4.6M YoY; adjusted EBITDA loss $2.4M.
- Total revenue $11.5M (Advanced Energy -6% to $9.3M; OEM +3% to $2.2M).
-
22 patients received single-session treatment combining Avéli subcision and Renuvion helium plasma RF.
-
Renuvion + liposuction shows higher satisfaction, lower revision rates in 113-patient study
Patients with Renuvion reported higher satisfaction with excess skin: Body-Q score 87.8 vs 73.8 (p=0.03).
-
Apyx Medical receives FDA clearance for power liposuction on AYON Body Contouring System
Expanded FDA 510(k) clearance for AYON Body Contouring System to include power liposuction, a reciprocating cannula for efficient fat removal.
-
Apyx Medical Q1 revenue $12.5M (+32% YoY); raises FY2026 guidance
Total revenue $12.5M, up 32% YoY; Surgical Aesthetics grew 36% to $10.7M.
-
Apyx Medical Q4 revenue record $19.2M, net loss narrows; FY2026 guidance $57.5-58.5M
Q4 total revenue record $19.2M, +34.7% YoY; Surgical Aesthetics +38.1% to $16.7M driven by AYON launch.
-
Apyx Medical reports preliminary Q4 revenue up ~34% YoY; Surgical Aesthetics up 38%
Total Q4 revenue expected $19.0-19.2M, up ~34% YoY; FY revenue $52.7-52.9M, up ~10%.
-
Apyx Medical files Certificate of Amendment to delete Article EIGHTH from charter
Stockholders approved the amendment at the August 7, 2025 annual meeting.
-
Apyx Medical prices $10M public offering of 2.76M shares at $3.62/share
Offering of 2,762,431 shares priced at $3.62 per share, with gross proceeds ~$9.4M.
-
Apyx Medical Q3 rev $12.9M (+12% YoY); net loss $2.0M; raises FY guidance to $50.5-52.5M
Total revenue $12.9M (+12% YoY); Surgical Aesthetics $11.1M (+19% YoY).
-
All five director nominees elected with wide margins; broker non-votes ~6.8M.
-
Apyx Medical Q2 revenue $11.4M, net loss $3.8M; raises FY2025 revenue guidance to $50-52M
Q2 total revenue $11.4M vs $12.1M YoY; Advanced Energy flat at $9.7M, OEM down 28.5% to $1.7M.
-
Apyx Medical receives FDA 510(k) clearance for AYON Body Contouring System
AYON is the first FDA-cleared all-in-one platform combining fat removal, contouring, tissue contraction, and electrosurgery.
-
Apyx Medical Q1 revenue $9.4M (-8% YoY), Advanced Energy +6%, net loss narrows to $4.2M
Net loss attributable to stockholders $4.2M ($0.10/sh) vs $7.6M ($0.22/sh) prior year; adjusted EBITDA loss $2.4M vs $5.3M.
-
First prospective RCT (Barone, 76 patients) shows Renuvion improves abdominal skin laxity and satisfaction scores vs lipoabdominoplasty alone.
-
Q4 total revenue $14.2M (-3% YoY); Advanced Energy flat at $12.1M. Full year revenue $48.1M (-8%).
-
Apyx Medical names Shawn Roman COO with $305,760 base salary, bonus target ≥50%
Shawn Roman appointed COO effective Jan 28, 2025; base salary $305,760.52.
-
Apyx Medical prelim Q4 rev $14.1-14.3M; Advanced Energy up >25% QoQ
Total Q4 revenue $14.1-14.3M, down ~3-4% YoY; Advanced Energy ~$12.0-12.2M (flat YoY).
-
Apyx submits 510(k) for AYON Body Contouring System; ahead of schedule
Submitted 510(k) premarket notification to FDA for AYON Body Contouring System.
-
Apyx Medical Q3 revenue down 4% to $11.5M; cuts FY24 guidance; workforce –25%
Net loss $4.7M ($0.14/share) vs $4.6M YoY; adjusted EBITDA loss $2.4M.
-
Apyx Medical annual meeting elects all eight director nominees and ratifies auditor
Stockholders elected all eight director nominees; votes in favor ranged from 13.2M to 14.1M.
-
Apyx Medical Q2 revenue falls 10% to $12.1M; net loss widens; updates FY2024 guidance
Revenue $12.1M (-10% YoY); Advanced Energy -17% to $9.8M, OEM +29% to $2.4M.
-
Andrew Makrides retired as Chairman effective May 7, 2024, after serving since 1982.
-
Apyx Medical Q1 revenue $10.2M (-16% YoY); net loss $7.6M; Chairman retires
Total revenue $10.2M (-16% YoY); Advanced Energy $7.5M (-23%); OEM $2.8M (+14%).
-
Q4 2023 Advanced Energy revenue $12.1M (+15% YoY); net loss $9.6M ($0.28/shr) vs $6.0M ($0.17) a year ago.
Executive changes
Departed
Michael Geraghty
Director
APYX ·
Apyx Medical Corp
On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.
Departed
John Andres
Director
APYX ·
Apyx Medical Corp
On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.
Appointed
Shawn D. Roman
Chief Operating Officer
APYX ·
Apyx Medical Corp
On November 6, 2024, the Board appointed Shawn D. Roman as the Chief Operating Officer of the Company, effective immediately.
Departed
Craig Swandal
Director
APYX ·
Apyx Medical Corp
On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.
Departed
Andrew Makrides
Chairman of the Board
APYX ·
Apyx Medical Corp
On May 7, 2024, Andrew Makrides announced his retirement as a director and Chairman of the Board, effective on the same date.
Appointed
Stavros Vizirgianakis
Director and Chairman of the Board
APYX ·
Apyx Medical Corp
On May 7, 2024, the Board appointed Mr. Vizirgianakis to serve as a director and Chairman of the Board, to fill the vacancy created by the retirement of Andrew Makrides.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.62 · Most common event earnings